vTv Therapeutics (VTVT) EBIT (2014 - 2026)

vTv Therapeutics has disclosed EBIT across 13 years of filings, most recently posting -$13.9 million for Q2 2026.

• In Q2 2026, EBIT fell 80.42% year-over-year to -$13.9 million; the TTM figure through Jun 2026 stood at -$9.3 million (up 63.89% YoY), while the FY2025 annual figure was -$32.8 million, down 35.68% from the prior year.
• EBIT came in at -$13.9 million for Q2 2026 at vTv Therapeutics, down from $23.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $23.3 million in Q1 2026 to a low of -$13.9 million in Q2 2026.
• Average EBIT over 5 years is -$5.3 million, with a median of -$6.5 million recorded in 2022.
• Year-over-year, EBIT tumbled 254.9% in 2022 and soared 457.73% in 2026.
• Over 5 years, EBIT stood at -$6.3 million in 2022, then gained by 25.79% to -$4.7 million in 2023, then dropped by 3.93% to -$4.9 million in 2024, then plunged by 61.18% to -$7.9 million in 2025, then sank by 76.66% to -$13.9 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$13.9 million in Q2 2026, $23.3 million in Q1 2026, and -$7.9 million in Q4 2025.